Respiratory Antiviral Treatment Market to surpass revenue of US$ 5.3 Bn by the end of 2030

Healthcare Facilities Increase Influenza and COVID-19 Testing Due to Ongoing Flu Season

The coronavirus (COVID-19) outbreak has sparked concern among individuals suffering from influenza. Due to similarities in symptoms, healthcare institutes are increasing awareness about the differences in symptoms. Though influenza and COVID-19 are both contagious respiratory illnesses, they are caused by different viruses. This confusion has created revenue opportunities for companies in the respiratory antiviral treatment market, since infected individuals are seeking professional help from doctors to identify the symptoms.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111841

Influenza is a serious medical issue in western countries. A second wave of COVID-19 in European countries is likely to compromise healthcare facilities. Hence, healthcare professionals are identifying people at high risk of acquiring influenza and COVID-19, and are recommending preventive measures to minimize the pressure in healthcare facilities.

RSV-associated Clinical Trails Holds Promising Potentials for Development of Bronchiolitis Antivirals

Innovations in the treatment of respiratory syncytial virus (RSV) infection hold promising potentials for the bronchiolitis treatment. For instance, Ark Biosciences— a biotech company specializing in therapeutics for viral infections and respiratory illnesses has announced a successful completion of the phase 2 proof-of-concept study for Ziresovir (AK0529), which is an antiviral agent. Bronchiolitis has led to several hundreds of thousands of deaths worldwide, especially of children under five years of age. Hence, companies in the respiratory antiviral treatment market are increasing their research capabilities to develop therapeutics for bronchiolitis in infants.

Current antiviral agents developed by companies in the respiratory antiviral treatment market are found to have clinical benefits but are not licensed by healthcare institutions. Companies are increasing efforts to develop antivirals that are effective in reducing signs and symptoms of bronchiolitis in infants.

Government-funded Grants Accelerate Development of Influenza Antivirals

Several new direct-acting influenza antivirals have been introduced in the respiratory antiviral treatment market. As such, baloxavir marboxil has been approved in the U.S., which is an antiviral for the treatment of influenza. However, there is a need to develop a universal influenza vaccine. Hence, healthcare companies are increasing their R&D capabilities to propose strategic plans ahead of government agencies with the help of field experts. On the other hand, manufacturers in the respiratory antiviral treatment market are increasing efforts to improve current seasonal influenza vaccines.

In order to tap into incremental opportunities in Europe, manufacturers are developing intravenous zanamivir-like antivirals, which is the only licensed treatment for influenza. This explains why the market is projected to expand at a CAGR of ~6% during the assessment period. Companies are achieving clinical developments in selected neuraminidase inhibitors, host-directed therapies, and selected polymerase inhibitors. Celdara Medical— a biotechnology-based company in the U.S. is gaining recognition for receiving Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop antivirals for COVID-19 and influenza.

Healthcare Providers Adopting Optimal Control Strategies to Overcome Issue of Drug Resistance

The respiratory antiviral treatment market is expected to surpass revenue of US$ 5.3 Bn by the end of 2030. However, the issue of antiviral resistance is emerging as a restraint for market growth. For instance, M2 ion-channel inhibitors and neuraminidase (NA) inhibitors are approved treatments for influenza; however, they are associated with drug resistance in individuals. As such, neuraminidase inhibitors are being used on an extensive scale as an anti-influenza drug, since this treatment is less susceptible to drug resistance.

Since drug resistance has led to increased cost of patient healthcare, companies in the respiratory antiviral treatment market are shifting their business models toward the development of vaccines to curb the spread of respiratory illnesses. Since coinfection of pneumonia and influenza has led to increased morbidity and mortality, healthcare providers are adopting optimal control strategies.

Antiviral Therapies Emerge as Alternative to Influenza Vaccines in High-risk Patients

The antiviral treatment is being highly preferred to shorten the duration of influenza symptoms. Moreover, these antivirals help to decrease the length of hospitals stays and minimizes the risk of complications in patients. As suggested by the CDC (Centers for Disease Control and Prevention), antiviral therapies help to improve medical outcomes in high-risk patients. As such, antiviral chemoprophylaxis is gaining increased popularity for influenza prevention and is being used as an adjunct to vaccination. Companies in the respiratory antiviral treatment market are boosting their output capacity to produce antiviral chemoprophylaxis meant for high-risk patients who cannot receive vaccination due to medical reasons.

Since high-risk patients such as pregnant women are susceptible to contraindications by vaccines, companies in the respiratory antiviral treatment market are increasing awareness about antiviral chemoprophylaxis to treat influenza. Patients with insufficient immune response are also recommended with antiviral chemoprophylaxis.

Immunoglobulins with Antiviral Drugs Help Reduce Symptoms of Measles

Companies in the respiratory antiviral treatment market are innovating in antiviral drugs to treat measles. However, their effectiveness after central nervous system (CNS) manifestations remain to be evaluated. Companies in the respiratory antiviral treatment market are experimenting with immunoglobulins to treat measles infection. The combination treatment is being highly publicized for measles treatment, which involves the use of immunoglobulins with antiviral drugs to reduce signs and symptoms.

Ribavirin is a popular antiviral drug used for the treatment of measles infection. The combination of ribavirin and immune serum globulin holds promising potentials to reduce respiratory symptoms of measles. Companies are conducting clinical trials to identify whether the action of vitamin A helps in the treatment of measles. Though vaccines are considered as the most efficient prevention of against measles, the decreasing coverage combined to the increasing number of immunocompromised people difficult to vaccinate confirm the necessity to develop efficient antiviral drugs.

Analysts’ Viewpoint

Healthcare institutes are offering funding to biotech companies to develop antiviral drugs that treat influenza and COVID-19. Direct-acting influenza antivirals are being preferred by healthcare providers to minimize symptoms of respiratory illnesses in patients. However, drug resistance is emerging as a problem in healthcare settings, resulting in increased cost of hospital stay. Hence, companies in the respiratory antiviral treatment market should increase awareness about optimal control strategies such as vaccines and isolation, if patients have low immune response toward antiviral drugs. The combination treatment of immunoglobulins with antiviral drugs helps to reduce signs and symptoms of the measles infection. Ribavirin is being highly publicized as an antiviral drug for the treatment of measles.

Respiratory Antiviral Treatment Market: Overview

Antiviral drugs are therapeutics that prevent the development and replication of virus without affecting host cells. These drugs do not destroy their target virus, as it is an obligatory intracellular parasite. Instead, these inhibit their propagation by deactivating viral enzymes.

Antiviral drugs are utilized to treat various types of respiratory conditions such as influenza, bronchiolitis, upper respiratory tract infections (URTI), pneumonia, and measles due to their effectiveness

The global respiratory antiviral treatment market has experienced significant growth in the last decade due to rise in prevalence of respiratory viral diseases and favorable policies

Different types of therapeutics are used in the treatment of respiratory viral diseases, including nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. Neuraminidase inhibitors are most commonly used in the treatment of respiratory viral diseases.

Respiratory Antiviral Treatment: Market Drivers

Rise in prevalence and incidence of respiratory viral diseases such as influenza, bronchiolitis, and others drives demand for respiratory antiviral treatment. Incidence and prevalence of flu are gradually increasing across the globe. According to the CDC, around 5% to 20% of the population is affected with the flu in the U.S. every year. Additionally, an estimated 200,000 people are hospitalized due to flu infection in the country every year; of these 36,000 succumb to flu complications.

Favorable policies for treatment and prevention of respiratory viral diseases are projected to drive the global respiratory antiviral treatment market during the forecast period. For instance, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) publishes recommendations for high-risk groups. It offers references for use of antiviral agents for treatment and prevention of respiratory viral diseases.

Market Segmentation: Respiratory Antiviral Treatment Market

In terms of drug class, the global respiratory antiviral treatment market has been divided into nucleoside analogs, neuraminidase inhibitors, ion channel blockers, and fusion protein inhibitors. The nucleoside analogs segment has been split into ribavirin, acyclovir, and others. The neuraminidase inhibitors segment has been sub-divided into oseltamivir, zanamivir, and others. The neuraminidase inhibitors segment is anticipated to dominate the global respiratory antiviral treatment market during the forecast period.

Based on disease type, the global respiratory antiviral treatment market has been classified influenza, bronchiolitis, pneumonia, upper respiratory tract infections (URTIs), and others (measles, etc.)

In terms of distribution channel, the global respiratory antiviral treatment market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the global respiratory antiviral treatment market in terms of revenue in 2019.

Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The report provides current and expected revenue (US$ Mn) for each of these segments from 2018 to 2030, considering 2019 as the base year. The compound annual growth rate (% CAGR) has been provided for each segment and market from 2020 to 2030, along with market size estimations.

Regional Overview: Respiratory Antiviral Treatment Market

The global respiratory antiviral treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions have been divided into major countries and sub-regions.

The current and expected market revenue (US$ Mn) of these regional markets and their major countries have been provided in the report from 2018 to 2030, with their CAGRs from 2020 to 2030

The study also offers a list of recommendations, highlights, and useful insights of the global respiratory antiviral treatment market, which would help new companies willing to enter the market and existing companies to increase market shares, and in the decision-making process

Major Players

The respiratory antiviral treatment market report concludes with the company profiles section, which includes key information about major players in the global respiratory antiviral treatment market

Leading players analyzed in the respiratory antiviral treatment market report include

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Pfizer, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc
• Mylan Inc.
• Merck & Co., Inc.
• AstraZeneca plc.

Each of these players has been profiled in the respiratory antiviral treatment market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments

Key Questions Answered in Respiratory Antiviral Treatment Market Report

• What is the sales/revenue generated by respiratory antiviral treatment across all regions during the forecast period?
• What are the opportunities in the global respiratory antiviral treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which drug class segment is expected to generate the highest revenue globally in 2030? Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Respiratory Antiviral Treatment Market – Segmentation

Drug Class

• Nucleoside Analogs
• Neuraminidase Inhibitors
• Ion Channel Blockers
• Fusion Protein Inhibitors

Disease Type

• Influenza
• Bronchiolitis
• Pneumonia
• Upper Respiratory Tract Infections (URTIs)
• Others (Measles, etc.)

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111841/2900